Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Serotonin Syndrome × Octreotide × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 12 Carcinoid Tumor 6 Somatostatinoma 4 Neoplasms 4 Insulinoma 4 Glucagonoma 4 Carcinoma, Islet Cell 4 Vipoma 3 Gastro-enteropancreatic neuroendocrine tumor 3 Gastrinoma 3 Adenoma, Islet Cell 3 Neoplasm Metastasis 2 Carcinoma, Medullary 2 Carcinoma 2 Zollinger-Ellison Syndrome 1 Serotonin Syndrome 1 Pituitary Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neuroendocrine Tumor G2 1 Neoplastic Cells, Circulating 1 Malignant Carcinoid Syndrome 1 Head and Neck Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Acromegaly 1

Interventions

telotristat ethyl 3 lanreotide 2 pasireotide 1 lutetium Lu 177 dotatate 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Random Allocation 1 Panitumumab 1 Octreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡